United States - English - NLM (National Library of Medicine)

micro labs limited - tafluprost (unii: 1o6wq6t7g3) (tafluprost - unii:1o6wq6t7g3) - tafluprost ophthalmic solution, 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. none. pregnancy category c. teratogenic effects: in embryo-fetal development studies in rats and rabbits, tafluprost administered intravenously was teratogenic. tafluprost caused increases in post-implantation losses in rats and rabbits and reductions in fetal body weights in rats. tafluprost also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and spine malformations in rabbits. in rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid that were 343 times the maximum clinical exposure based on c max . in rabbits, effects were seen at a tafluprost dose of 0.03 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid during organogenesis that were approximately 5 times higher than the

United States - English - NLM (National Library of Medicine)

sandoz inc - tafluprost (unii: 1o6wq6t7g3) (tafluprost - unii:1o6wq6t7g3) - tafluprost ophthalmic solution 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. none. teratogenic effects in embryo-fetal development studies in rats and rabbits, tafluprost administered intravenously was teratogenic. tafluprost caused increases in post-implantation losses in rats and rabbits and reductions in fetal body weights in rats. tafluprost also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and spine malformations in rabbits. in rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid that were 343 times the maximum clinical exposure based on cmax . in rabbits, effects were seen at a tafluprost dose of 0.03 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid during organogenesis that were approximately 5 times higher than the clinical exposure based on cmax . at t

United States - English - NLM (National Library of Medicine)

prasco laboratories - tafluprost (unii: 1o6wq6t7g3) (tafluprost - unii:1o6wq6t7g3) - tafluprost ophthalmic solution 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. none. pregnancy category c. teratogenic effects: in embryo-fetal development studies in rats and rabbits, tafluprost administered intravenously was teratogenic. tafluprost caused increases in post-implantation losses in rats and rabbits and reductions in fetal body weights in rats. tafluprost also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and spine malformations in rabbits. in rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid that were 343 times the maximum clinical exposure based on cmax . in rabbits, effects were seen at a tafluprost dose of 0.03 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid during organogenesis that were approximately 5 times higher than the clinical exposu

United States - English - NLM (National Library of Medicine)

akorn - tafluprost (unii: 1o6wq6t7g3) (tafluprost - unii:1o6wq6t7g3) - tafluprost 0.0045 mg in 0.3 ml - zioptan® (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. none. pregnancy category c. teratogenic effects: in embryo-fetal development studies in rats and rabbits, tafluprost administered intravenously was teratogenic. tafluprost caused increases in post-implantation losses in rats and rabbits and reductions in fetal body weights in rats. tafluprost also increased the incidence of vertebral skeletal abnormalities in rats and the incidence of skull, brain and spine malformations in rabbits. in rats, there were no adverse effects on embryo-fetal development at a dose of 3 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid that were 343 times the maximum clinical exposure based on cmax . in rabbits, effects were seen at a tafluprost dose of 0.03 mcg/kg/day corresponding to maternal plasma levels of tafluprost acid during organogenesis that were approximately 5 times higher than the cli

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - tafluprost, quantity: 0.015 mg/ml - eye drops - excipient ingredients: polysorbate 80; glycerol; sodium hydroxide; monobasic sodium phosphate dihydrate; water for injections; disodium edetate; hydrochloric acid - saflutan is indicated for the reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension, as monotherapy or as adjunctive therapy to beta blockers.

United States - English - NLM (National Library of Medicine)

the ritedose corporation - tafluprost (unii: 1o6wq6t7g3) (tafluprost - unii:1o6wq6t7g3) -

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nitto medic co., ltd. - tafluprost - limpid and colorless, aqueous ophthalmic solution, 2.5ml, (cap) blue-green, (label) white label with blue-green bands and line and pale red line, (bottle) clear

Israel - English - Ministry of Health

rafa laboratories ltd - tafluprost - ophthalmic solution - tafluprost 15 mcg/ml - tafluprost - tafluprost - reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.as monotherapy in patients • who would benefit from preservative free eye drops • insufficiently responsive to first line therapy • intolerant or contra-indicated to first line therapyas adjunctive therapy to beta-blockers.

Malta - English - Malta Medicines Authority

santen oy niittyhaankatu 20, 33720 tampere, finland - tafluprost, timolol maleate - eye drops, solution - tafluprost 15 µg/ml timolol maleate 5 mg/ml - ophthalmologicals

Malta - English - Malta Medicines Authority

santen oy niittyhaankatu 20, 33720 tampere, finland - tafluprost - eye drops, solution - tafluprost 15 µg/ml - ophthalmologicals